Exercise improves strength, fitness and functional capacity in breast cancer: meta-analysis of 68 randomized trials finds supervised resistance and combined programs most effective

Table of Contents

1. Key Highlights
2. Introduction
3. How the evidence was assembled
4. Who participated in the trials
5. What the exercise programs looked like
6. Quality of the evidence and heterogeneity
7. Primary results: what exercise does — domain by domain
8. Which program elements make the difference?
9. Safety and special considerations
10. Translating evidence to practice: practical prescriptions grounded in the data
11. Real‑world examples from the trial literature
12. Limitations, uncertainties and research priorities
13. Practical checklist for clinicians and rehabilitation teams
14. FAQ

Key Highlights

• Meta-analysis of 68 randomized controlled trials (4,158 women) found exercise produced moderate-to-large improvements in muscular strength, functional exercise capacity (FEC), and cardiorespiratory fitness; fat‑free mass increased with a small but significant effect.
• Program features matter: resistance training produced the largest strength gains; combined aerobic + resistance training increased fat‑free mass; supervised programs and interventions lasting >12 weeks were consistently more effective than unsupervised or very short programs.

Introduction

Clinicians, rehabilitation specialists and patients face repeated questions about what kind of exercise helps women with breast cancer recover physical capacity and preserve body composition. Randomized controlled trials over the past two decades have tested myriad approaches — aerobic training, resistance training, combined programs, home‑based walking, high‑intensity interval training (HIIT), Pilates, Tai Chi and device‑assisted interventions — but findings have often arrived in fragmented form. A comprehensive meta‑analysis that pooled results from 68 randomized controlled trials now clarifies how exercise affects four objective domains: muscular strength, fat‑free mass, functional exercise capacity (FEC) and cardiorespiratory fitness. The evidence shows clear, clinically meaningful benefits across multiple outcomes, and identifies program elements that most reliably produce those benefits. This analysis offers the strongest synthesis to date to guide exercise prescription across the treatment continuum: prehabilitation, during active treatment and post‑treatment survivorship.

How the evidence was assembled

A systematic search across major scientific databases retrieved 2,979 candidate publications. After deduplication, title/abstract screening and full‑text review, 68 randomized controlled trials (RCTs) met inclusion criteria and entered the quantitative synthesis. Those RCTs included 4,158 women with stage I–III breast cancer (2,100 in exercise groups and 2,058 controls). Trials were published between 2001 and 2024 and reported in English. The selection process included checks against previous systematic reviews and follow‑up with investigators for incomplete data; additional information was received for a single trial after contact, and seven studies were excluded due to missing essential data.

The review separated the body of evidence by physical outcome domain (muscular strength, fat‑free mass, FEC, cardiorespiratory fitness) and by cancer‑care phase (pre‑treatment, active treatment, post‑treatment). Subgroup and stratified meta‑analyses examined how mode of exercise (resistance, aerobic, combined), supervision, intervention duration, session frequency and intensity influenced outcomes. Risk of bias was assessed with Version 2 of the Cochrane tool.

Who participated in the trials

Aggregate trial participants averaged about 52 years of age (intervention group mean 52.4 ± 8.1 years; control group mean 52.3 ± 8.4 years). All trials enrolled women with stage I–III disease. Timing varied: 64% of trials assessed exercise after primary cancer treatment, 33% during active treatment (chemotherapy and/or radiotherapy), and only two RCTs examined pre‑treatment or prehabilitation effects.

Across outcome domains:

• Muscular strength: 39 RCTs (control N ≈ 1,176; intervention N ≈ 1,183), mean age ≈ 51.8 years.
• Fat‑free mass: 39 RCTs (control N ≈ 1,071; intervention N ≈ 1,115), mean age ≈ 52.8 years.
• Functional exercise capacity (FEC): 12 RCTs (control N ≈ 305; intervention N ≈ 308), mean age ≈ 51.1 years.
• Cardiorespiratory fitness (VO2 or similar): 18 RCTs (control N ≈ 632; intervention N ≈ 656), mean age ≈ 52.1 years.

Diversity of participants — in terms of ethnicity, comorbidities and baseline fitness — varied across trials. Several larger multicenter trials and behavior‑change interventions contributed to heterogeneity across study populations and settings, from supervised center‑based programs to home‑based or wearable‑guided protocols.

What the exercise programs looked like

Program characteristics varied widely across the 68 RCTs, but common patterns emerged.

Duration and frequency

• Average intervention duration across studies: 18.6 weeks (range 1 week to 52 weeks).
• For muscular strength trials the mean was 18.2 weeks (range 1–52 weeks).
• For fat‑free mass trials the mean was 19.7 weeks (range 4–52 weeks).
• For cardiorespiratory fitness trials the mean was 11.8 weeks (range 4–27 weeks).
• Most trials required exercise three or more times per week (58% overall); however, frequency differed by outcome domain — more than half of strength and cardiorespiratory trials used ≥3 sessions/week, while slightly more than half of fat‑free mass trials reported ≤2 sessions/week.

Mode of exercise

• Combined aerobic + resistance training was the most common single mode across the pool (about 48% of trials overall and prominent among trials assessing FEC and fat‑free mass).
• Aerobic‑only interventions represented roughly 28% overall and were predominant among trials measuring cardiorespiratory fitness.
• Resistance‑only interventions were less common but prominent in strength‑focused trials and showed the largest strength gains.

Supervision and intensity

• Approximately two‑thirds of trials involved supervised exercise (about 67% overall), with strength and cardiorespiratory fitness trials especially likely to be supervised.
• Intensity in most trials was moderate‑to‑high (≈60% of trials described moderate‑to‑high intensity), with HIIT and heavy‑load resistance protocols included in several contemporary trials.

Setting and delivery

• Delivery models included center‑based supervised programs, home‑based walking or wearable‑assisted aerobic training, telehealth or web‑based exercise systems (for example, web‑based chemo exercise programs), and hybrid designs. Trials testing wearable device‑based aerobic programs and online supervised home‑based models were present in the most recent literature.

Quality of the evidence and heterogeneity

Risk‑of‑bias assessment found concerns in most trials:

• 75% of RCTs had “some concerns” regarding risk of bias;
• 25% were judged as having “high” risk of bias;
• None of the included trials achieved a “low” risk of bias classification across all domains.

Problems most often related to incomplete reporting of the randomization process, allocation concealment and, in some cases, missing outcome data or deviations from intended intervention. These limitations reduce the certainty of pooled estimates and argue for careful interpretation of subgroup differences.

Statistical heterogeneity (I2) varied across outcomes. Fat‑free mass exhibited low heterogeneity; muscular strength, FEC and cardiorespiratory fitness showed moderate‑to‑high heterogeneity in many pooled comparisons. Prediction intervals indicated potential variability in the effects that future trials might observe, a finding consistent with the diversity of program designs, participant characteristics and outcome measurement tools across studies.

Primary results: what exercise does — domain by domain

Muscular strength

• Number of trials: 39 RCTs (≈2,359 participants combined).
• Overall effect: Exercise significantly increased muscular strength with moderate‑to‑large pooled effects.
• Treatment‑phase findings: Strength increased significantly during active treatment and post‑treatment (both moderate‑to‑large effects). Data were insufficient to draw firm conclusions about pre‑treatment effects.
• Program features: Resistance training produced greater strength gains than aerobic or combined modes (statistically significant difference, p < 0.01). Supervised programs drove the effect; unsupervised interventions did not produce significant strength improvements. Frequency, duration (within the range tested) and intensity did not show consistent differential effects on strength in pooled subgroup tests.

Clinical interpretation: Resistance training — ideally supervised and delivered multiple times per week — is the most reliable method to restore or preserve muscle strength in women receiving chemotherapy or in the survivorship phase. Trials with heavy‑load or maximal strength components reported the largest gains, consistent with principles of progressive overload.

Fat‑free mass

• Number of trials: 39 RCTs (≈2,186 participants).
• Overall effect: Exercise yielded a small but statistically significant increase in fat‑free mass.
• Treatment‑phase findings: Fat‑free mass improved post‑treatment with a low effect size, but not reliably in pre‑treatment or during active treatment.
• Program features: Combined aerobic + resistance programs were the only mode to produce significant fat‑free mass gains. Supervision was a major driver; unsupervised programs showed no effect. Interventions exceeding 12 weeks and frequencies of ≥3 sessions per week were associated with small but significant increases in fat‑free mass. Intensity did not show consistent effects.

Clinical interpretation: Adding structured resistance to aerobic work — and maintaining the program for longer than three months with supervision and sufficient weekly frequency — offers the best chance to increase lean tissue. Gains are modest on average, but they may be clinically meaningful for patients vulnerable to treatment‑related sarcopenia or menopausal bone/lean mass loss.

Functional exercise capacity (FEC)

• Number of trials: 12 RCTs (≈613 participants).
• Overall effect: Exercise substantially improved FEC with large pooled effects.
• Treatment‑phase findings: Improvements were observed during both active treatment and post‑treatment, with large effect sizes in both phases.
• Program features: Stratified analyses did not show statistically significant differences in FEC by mode, supervision, duration, frequency or intensity, suggesting that a range of exercise approaches can boost functional capacity when implemented appropriately.

Clinical interpretation: Functional improvements — measured by tests such as the 6‑minute walk test or similar performance measures — respond robustly to exercise both during chemotherapy/radiation and afterward. Even modest programs that include aerobic and some strength elements can translate into meaningful gains in walking speed, endurance and daily function.

Cardiorespiratory fitness

• Number of trials: 18 RCTs (≈1,288 participants).
• Overall effect: Exercise produced significant improvements in cardiorespiratory fitness with moderate‑to‑large effects in pooled analysis.
• Treatment‑phase findings: Cardiorespiratory fitness improved significantly during active treatment with large effect sizes; evidence for pre‑ or post‑treatment effects was less consistent across trials.
• Program features: Aerobic and combined aerobic + resistance programs produced significant VO2/fitness gains; resistance‑only programs did not. Supervised programs showed greater effects than unsupervised programs. Interventions longer than 12 weeks achieved larger improvements than shorter programs. Frequency and intensity did not systematically modify outcomes in the pooled tests, though studies that used higher‑intensity aerobic work — including interval formats — tended to report larger improvements in trials with careful supervision.

Clinical interpretation: To improve cardiorespiratory fitness, prioritize aerobic training or combined programs, ensure supervision when feasible, and aim for programs of sufficient duration (≥12 weeks). Improvements during active treatment indicate that women undergoing chemotherapy can safely achieve cardiorespiratory gains with properly tailored programs.

Which program elements make the difference?

The meta‑analysis tested how mode, supervision, duration, frequency and intensity influenced outcomes.

Mode

• Strength: Resistance training superior to aerobic or combined modes for muscular strength gains.
• Fat‑free mass: Combined aerobic + resistance training the only mode with significant increases.
• Cardiorespiratory fitness: Aerobic work produced the largest effects; combined programs also effective; resistance alone did not improve VO2.

Supervision

• Supervised programs consistently outperformed unsupervised programs for strength and fat‑free mass. For cardiorespiratory fitness, supervised programs were also superior.
• Unsupervised home programs, walking prescriptions and minimal‑contact interventions sometimes improved FEC or subjective outcomes, but they were less reliable at producing objective strength or lean mass gains.

Duration and frequency

• Programs longer than 12 weeks were more likely to improve fat‑free mass and cardiorespiratory fitness. Strength gains appeared across a range of durations but supervision and resistance emphasis mattered more than duration alone.
• Frequencies of three or more sessions per week were associated with better outcomes for strength and fat‑free mass.

Intensity

• Over the trials, more than half described moderate‑to‑high intensity. Intensity alone did not show clear differential effects in pooled subgroup tests, likely because intensity interacts with supervision, progression and adherence. Trials using heavy‑load resistance or HIIT components reported larger physiological responses where implementation was rigorous and supervised.

Heterogeneity and effect variability

• Across analyses the predicted intervals and I2 statistics showed moderate‑to‑high heterogeneity for strength, FEC and cardiorespiratory fitness, suggesting that not all programs produce uniform benefits. Fat‑free mass responses were less heterogeneous.
• Sources of heterogeneity include baseline fitness, concurrent therapies (types and timing), variability in adherence, exercise fidelity, measurement instruments and small sample sizes in some trials.

Safety and special considerations

Safety was an implicit concern across trials. The pooled evidence includes trials specifically addressing safety questions such as lymphedema development and resistance training after axillary surgery. Earlier landmark trials (for instance, weight‑training safety trials from the mid‑2000s) demonstrated that progressive resistance training does not increase lymphedema risk when programs are implemented carefully, and more recent trials continue to confirm the safety and feasibility of strength work during and after treatment.

Specific safety considerations for program design:

• Start with a supervised, individualized assessment when possible, particularly for women with recent surgery, cardiac risk factors (e.g., anthracycline exposure), bone‑health concerns or multiple comorbidities.
• Monitor symptoms and treatment side effects (fatigue, neuropathy, cardiotoxicity) and adjust load, volume and modality accordingly.
• For patients on cardiotoxic agents, incorporate cardio‑oncology guidance; exercise‑based cardio‑oncology rehabilitation studies suggest exercise can mitigate cardiotoxic risk markers when applied cautiously.
• Incorporate progressive overload principles for resistance work but advance conservatively in the presence of persistent neuropathy, poorly controlled blood pressure or other significant medical issues.

Translating evidence to practice: practical prescriptions grounded in the data

The meta‑analysis offers clear, evidence‑based direction for clinicians and rehabilitation teams designing exercise programs for women with breast cancer. The following synthesis converts pooled findings into practical, implementable recommendations while acknowledging heterogeneity and individual variation.

For improving muscular strength

• Core prescription: supervised resistance training, 2–3 sessions per week minimum, progressing toward 3+ sessions/week when tolerated.
• Load and progression: aim for progressive resistance (e.g., 8–12 repetition ranges for hypertrophy and strength build, with heavier loads and lower rep ranges introduced under supervision for maximal strength gains).
• Duration: expect measurable strength gains within 12–18 weeks; longer programs produce cumulative benefits.
• Safety: begin with lower loads after surgery; emphasize technique, limb‑specific protections for recent axillary surgery and graded progression for patients with neuropathy.

For increasing fat‑free mass (lean tissue)

• Core prescription: combined aerobic + resistance training, at least 12 weeks in duration and ideally three or more sessions per week.
• Resistance component: include compound movements that recruit large muscle groups; ensure adequate protein intake and address nutritional support when weight loss or sarcopenia is a concern.
• Supervision: supervised programs produced the only consistent fat‑free mass gains in pooled analyses.

For improving functional exercise capacity (FEC)

• Core prescription: any structured program that includes aerobic capacity work and some resistance or functional components. Walking‑based programs, supervised aerobic classes and combined interventions all improved FEC.
• Intensity: both moderate continuous and interval approaches worked; individual tolerance and treatment timing should guide intensity selection.
• Practical goal: aim for functional test improvements (e.g., 6‑minute walk distance, timed up‑and‑go) that translate into daily activities rather than isolated gym performance.

For enhancing cardiorespiratory fitness

• Core prescription: aerobic training (continuous or interval) or combined programs are effective; supervised delivery and interventions exceeding 12 weeks maximize gains.
• Frequency: 3+ sessions per week yields better VO2 responses than infrequent sessions.
• For patients undergoing active chemotherapy: supervised aerobic work can still produce significant fitness gains and should not be deferred automatically; tailor intensity and duration to side‑effect burden.

For delivery and access

• Supervision matters. Where center‑based supervision is not available, leverage hybrid models: initial supervised assessment and program setup followed by remote monitoring (telehealth, wearable devices, structured online sessions).
• Behavior‑change components (education, coaching, self‑monitoring) enhance adherence and may amplify long‑term benefits; multicenter behavior‑change trials in the dataset improved activity levels and aerobic fitness.
• Programs must be individualized for age, comorbidities, treatment stage, baseline fitness and personal goals.

Real‑world examples from the trial literature

Several trials within the pooled dataset illustrate how these principles work in practice.

• OptiTrain trial (concurrent resistance + HIIT during chemotherapy): demonstrated highly favorable physiological responses to a combined program delivered during active treatment. That trial underscores the feasibility of delivering intense, supervised exercise even while patients receive cytotoxic therapy.
• Web‑based and wearable‑assisted programs: more recent RCTs tested online supervised home‑based exercise systems and wearable device‑guided aerobic training during anthracycline‑based chemotherapy; these trials reported improvements in physical and mental health measures and suggest remote delivery can be effective when supervision and adherence strategies are built in.
• Heavy‑load strength training trials during adjuvant therapy: contemporary studies employing heavy resistance under supervision documented increases in muscle fiber size, myonuclear content and satellite cell markers in addition to strength gains, providing mechanistic support for load‑progression principles in this population.

Limitations, uncertainties and research priorities

The evidence base is substantial but not uniform. Limitations include:

• Risk of bias: no trial achieved uniformly low risk of bias; many had incomplete randomization reporting or other methodological concerns.
• Heterogeneity: moderate‑to‑high statistical heterogeneity for several pooled outcomes indicates variability in observed effects across trials.
• Underrepresentation of prehabilitation: only two RCTs studied pre‑treatment programs, leaving the prehabilitation evidence base thin relative to active and post‑treatment phases.
• Limited head‑to‑head trials comparing supervision models, low‑resource delivery or different intensities in adequately powered designs.
• Sparse long‑term follow‑up for durability of lean mass and functional gains, and for outcomes such as recurrence or survival.

Research priorities emerging from the analysis:

• Large, low‑risk RCTs comparing supervised versus remote/hybrid delivery, particularly in underserved settings.
• Trials with standardized measurement of lean mass (DXA), muscle strength and objective VO2 metrics, enabling cleaner pooling and dose‑response modeling.
• Prehabilitation RCTs that test functional and outcome metrics relevant to surgical recovery and short‑term treatment tolerance.
• Studies that evaluate cost, scalability and equity of supervised versus remotely supervised models.

Practical checklist for clinicians and rehabilitation teams

1. Assess baseline fitness, recent surgeries and cardiometabolic risk before prescribing exercise.
2. Prefer supervised programs for strength and lean‑mass goals whenever feasible.
3. Emphasize resistance training for strength restoration; include aerobic work to improve cardiorespiratory fitness and functional capacity.
4. Plan programs to run at least 12 weeks for lean‑mass and cardiorespiratory outcomes; strength gains can appear earlier but benefit from progressive, sustained training.
5. Target ≥3 sessions per week for programs aimed at strength and lean mass; adjust frequency based on tolerance and clinical constraints.
6. Use progressive overload with careful technique instruction; tailor intensity to treatment phase and side effects.
7. If supervision is unavailable, use hybrid approaches, wearable monitoring and structured telehealth coaching to enhance adherence and fidelity.
8. Monitor symptoms, chemotherapy‑related toxicities and cardiac status in patients receiving cardiotoxic agents; collaborate with oncology and cardio‑oncology colleagues.

FAQ

Q: Is exercise safe during chemotherapy and radiotherapy? A: Trials included in the meta‑analysis delivered exercise during active treatment in many cases. Supervised, individualized programs have been implemented safely and produced improvements in strength, FEC and cardiorespiratory fitness. Safety monitoring is essential; consult oncology and consider baseline cardiac evaluation if patients received or will receive cardiotoxic agents.

Q: What type of exercise should patients prioritize to get stronger? A: Resistance training. Trials that emphasized progressive resistance produced the largest and most reliable strength gains. Supervision amplifies strength improvements. Aim for structured resistance sessions at least twice weekly and progress toward three sessions per week when tolerated.

Q: Will exercise increase lean mass (fat‑free mass)? A: Yes, but the average effect is small. Combined aerobic + resistance programs, supervised and maintained for more than 12 weeks with a frequency of three or more sessions per week, produced consistent gains in fat‑free mass.

Q: Does aerobic exercise improve cardiorespiratory fitness during chemotherapy? A: Yes. Aerobic and combined programs improved cardiorespiratory fitness, and several trials showed substantial improvements even during active chemotherapy. Supervised delivery and interventions longer than 12 weeks maximized gains.

Q: Are home‑based and unsupervised programs effective? A: Home‑based programs can improve functional outcomes and increase activity levels, but unsupervised programs in the pooled data did not reliably increase muscular strength or lean mass. Hybrid models that include initial supervision, remote monitoring and coaching can broaden access while retaining effectiveness.

Q: How long does it take to see benefits? A: Strength gains can emerge within 8–12 weeks; meaningful changes in fat‑free mass and cardiorespiratory fitness are more likely after 12 weeks of consistent training. Functional exercise capacity often improves in both short and medium timeframes depending on the intervention.

Q: Does exercise increase the risk of lymphedema? A: Trials in the dataset, including earlier safety studies, indicate that progressive resistance training does not increase lymphedema risk when programs are supervised and use graded progression. Prescribe individualized, monitored strength protocols for patients with previous axillary surgery.

Q: Should all breast cancer survivors be referred to supervised exercise programs? A: Supervised programs are preferred when the clinical goal is objective strength or lean‑mass increases, or when patients have recently completed surgery or active treatment. Resource limitations may require triage; consider supervised program enrollment for those with significant deconditioning, sarcopenia risk or cardiometabolic concerns, and hybrid or remote options for others.

Q: What are the key gaps clinicians should watch for in future guidance? A: High‑quality head‑to‑head trials comparing supervision models, standardized reporting of exercise dose and fidelity, and robust prehabilitation trials remain necessary. Long‑term durability of physiologic gains, effects on survival and recurrence, and studies in diverse populations are priorities.

The meta‑analysis synthesizes a large and growing trial literature to reach a clear conclusion: exercise produces meaningful improvements in muscular strength, functional capacity and cardiorespiratory fitness for women with stage I–III breast cancer, and modest lean‑mass benefits when programs include both resistance and aerobic components. Supervision, resistance emphasis for strength, combined modes for lean mass, and program duration beyond 12 weeks emerge as reliable levers to boost outcomes. Clinicians should incorporate structured exercise — tailored for treatment phase and patient context — as a central component of recovery and survivorship care.